Cargando…

D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1

Breast cancer is the most frequent malignancy in women worldwide, and triple-negative breast cancer (TNBC) patients have the worst prognosis and highest risk of recurrence. The therapeutic strategies for TNBC are limited. It is urgent to develop new methods to enhance the efficacy of TNBC treatment....

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Ruonan, Yang, Yajing, Dong, Wenjing, Lin, Mingen, He, Jing, Zhang, Xinchao, Tian, Tongguan, Yang, Yunlong, Chen, Kun, Lei, Qun-Ying, Zhang, Song, Xu, Yanping, Lv, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2022
Materias:	Biological Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8872783/ https://www.ncbi.nlm.nih.gov/pubmed/35181605 http://dx.doi.org/10.1073/pnas.2114851119

Ejemplares similares

Publisher Correction: TET2 is required to suppress mTORC1 signaling through urea cycle with therapeutic potential
por: He, Jing, et al.
Publicado: (2023)

TET2 is required to suppress mTORC1 signaling through urea cycle with therapeutic potential
por: He, Jing, et al.
Publicado: (2023)

Targeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma
por: Lin, Mingen, et al.
Publicado: (2023)

Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy
por: Chen, Jie, et al.
Publicado: (2021)

Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation
por: Zhu, Lin, et al.
Publicado: (2022)

New insights and options into the mechanisms and effects of combined targeted therapy and immunotherapy in prostate cancer
por: Lin, Mingen, et al.
Publicado: (2023)

Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
por: Yang, Tinglin, et al.
Publicado: (2023)

Radiotherapy/Chemotherapy-Immunotherapy for Cancer Management: From Mechanisms to Clinical Implications
por: Li, Qian, et al.
Publicado: (2023)

Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers
por: Kong, Yuehong, et al.
Publicado: (2021)

Trypanosoma cruzi amastigote adhesion to macrophages is facilitated by the mannose receptor
Publicado: (1995)

FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer
por: Zhang, Yang, et al.
Publicado: (2022)

SLAMF8 expression predicts the efficacy of anti‐PD1 immunotherapy in gastrointestinal cancers
por: Zhang, Qun, et al.
Publicado: (2021)

Using triple radio-immunotherapy to overcome cancer immunotherapy resistance
por: Zhang, Zengfu, et al.
Publicado: (2023)

Intestinal microbial 16S sequencing and LC-MS metabonomic analysis revealed differences between young and old cats
por: Tian, Tongguan, et al.
Publicado: (2023)

Triple kill: DDR inhibitors, radiotherapy and immunotherapy leave cancer cells with no escape: DDR inhibitors, radiotherapy and immunotherapy can kill cancer cells
por: Qiu, Yuyue, et al.
Publicado: (2022)

Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment
por: Yu, Siting, et al.
Publicado: (2022)

Natural Blockers of PD-1/PD-L1 Interaction for the Immunotherapy of Triple-Negative Breast Cancer-Brain Metastasis
por: Nakhjavani, Maryam, et al.
Publicado: (2022)

The confluence of radiotherapy and immunotherapy
por: Burnette, Byron, et al.
Publicado: (2012)

Global research trends on anti-PD-1/anti-PD-L1 immunotherapy for triple-negative breast cancer: A scientometric analysis
por: Wu, Jinyao, et al.
Publicado: (2023)

Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer
por: Zhang, Anqi, et al.
Publicado: (2022)

Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Safety of thoracic radiotherapy after PD‐(L)1 inhibitor treatment in patients with lung cancer
por: Chen, Yu, et al.
Publicado: (2021)

The effect of postmastectomy radiotherapy in node-positive triple-negative breast cancer
por: Zhang, Lei, et al.
Publicado: (2020)

The Mannose-Binding Lectin: An Infection Susceptibility Gene
por: Ezekowitz, R. Alan, et al.
Publicado: (2005)

Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer
por: Ren, Yifan, et al.
Publicado: (2022)

PD-L1 degradation pathway and immunotherapy for cancer
por: Gou, Qian, et al.
Publicado: (2020)

An RNA–RNA crosstalk network involving HMGB1 and RICTOR facilitates hepatocellular carcinoma tumorigenesis by promoting glutamine metabolism and impedes immunotherapy by PD-L1+ exosomes activity
por: Wei, Yanping, et al.
Publicado: (2021)

Research progress on immunotherapy in triple-negative breast cancer (Review)
por: Zhang, Xiaoxiao, et al.
Publicado: (2022)

Correction: Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer
por: Li, Yanping, et al.
Publicado: (2023)

Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
por: Kumar, Sunny, et al.
Publicado: (2022)

Mannose-Modified Chitosan Poly(lactic-co-glycolic acid) Microspheres Act as a Mannose Receptor-Mediated Delivery System Enhancing the Immune Response
por: Feng, Haibo, et al.
Publicado: (2021)

Abscopal effect of stereotactic radiotherapy combined with anti‐PD‐1/PD‐L1 immunotherapy: Mechanisms, clinical efficacy, and issues
por: Zhuang, Hongqing
Publicado: (2020)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
por: Bie, Fenglong, et al.
Publicado: (2022)

Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma
por: Yan, Huiyu, et al.
Publicado: (2023)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Recent advances in biotransformation, extraction and green production of D-mannose
por: Wang, Peiyao, et al.
Publicado: (2021)

Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy
por: Lu, Fengkun, et al.
Publicado: (2021)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: A Case Report
por: Liu, Ze-Long, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_25n9mgsik782rt5j4cioi2st2l